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RFA Guardian: Comprehensive 
Simulation of Radiofrequency 
Ablation Treatment of Liver Tumors
Philip Voglreiter1, Panchatcharam Mariappan2, Mika Pollari3, Ronan Flanagan2,  
Roberto Blanco Sequeiros4, Rupert Horst Portugaller5, Jurgen Fütterer6,  
Dieter Schmalstieg1, Marina Kolesnik7 & Michael Moche8
The RFA Guardian is a comprehensive application for high-performance patient-specific simulation of 
radiofrequency ablation of liver tumors. We address a wide range of usage scenarios. These include 
pre-interventional planning, sampling of the parameter space for uncertainty estimation, treatment 
evaluation and, in the worst case, failure analysis. The RFA Guardian is the first of its kind that exhibits 
sufficient performance for simulating treatment outcomes during the intervention. We achieve this 
by combining a large number of high-performance image processing, biomechanical simulation and 
visualization techniques into a generalized technical workflow. Further, we wrap the feature set into a 
single, integrated application, which exploits all available resources of standard consumer hardware, 
including massively parallel computing on graphics processing units. This allows us to predict or 
reproduce treatment outcomes on a single personal computer with high computational performance 
and high accuracy. The resulting low demand for infrastructure enables easy and cost-efficient 
integration into the clinical routine. We present a number of evaluation cases from the clinical practice 
where users performed the whole technical workflow from patient-specific modeling to final validation 
and highlight the opportunities arising from our fast, accurate prediction techniques.
Radiofrequency ablation (RFA) of liver malignancies has become an important alternative therapy for patients 
who disqualify for standard surgical treatment or are in an early tumor stage1,2. When surgical resection is not 
feasible, RFA is the preferred treatment option for small liver tumors1,2. Moreover, patient recovery after surgical 
resection takes longer and post-procedural quality of life is lower than after RFA2.
While many more options for local cancer treatment exist (e.g. Cryo Ablation3, Irreversible Electroporation4 
or hyperthermia in conjunction with other treatment methods5,6), the clincial routine prefers RFA (or, occasion-
ally, microwave ablation) treatment for smaller liver tumors. Although microwave ablation has become more 
prevalent in the past years, no statistically significant difference in survival rates compared to RFA of smaller 
lesions (diameter below 3.5 cm) in the liver could be found7,8.
In RFA, interventional radiologists (IR) destroy malignant cells using percutaneous probes that induce heating 
in a locally delimited region around a tumor. Successful treatment is defined as complete ablation of the tumor 
with a safety margin of destroyed healthy tissue in its immediate vicinity.
However, clinical experience with RFA indicates a significant mismatch between expected and observed lesion 
size, leading to reduced survival rates due to over-treatment with severe injuries (up to 9%) or under-treatment 
with tumor recurrence9 (up to 40%). Further, Hildebrand et al.10 have shown that the survival rates after 1 and 2 
years significantly depend on the experience of the IR: Operating experience of 0–2 years resulted in 69%/46% 
(1/2 years) survival, while rates of 3–4 years experience corresponded to 92%/89%, respectively. Further, 
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treatment of tumors larger than 3 cm is known to yield a higher local recurrence and a lower survival rate11 due 
to cumulation of unpredictabilities for larger lesions. This is strongly influenced by patient-specific factors, such 
as blood perfusion12–14, location of the tumor15, needle positioning16–18 and device-specific parameters, such as 
delivery of power or impedance19,20 and number of possible heating cycles21. In addition, continuous monitoring 
of the lesion growth during ablation is technically extremely challenging and therefore not clinical feasible to date.
Mispredicting the lesion size can lead to over- or under-treatment with specific risks to the patient. Simulating 
and visualizing the treatment outcome as observed one month post-ablation could help even experienced IRs to 
prospectively reinforce their decision making process. In general, IRs of any experience level can benefit from 
software-assisted planning and simulation of RFA in many scenarios. However, previous approaches for compu-
tational simulation of RFA22,23 are too inefficient and time-consuming for exploring the vast parameter space or 
only provide approximations24. Additionally, many parallel approaches require distributed computing to acceler-
ate the simulation25, which can be difficult to integrate into clinical sites.
For intervention guidance, ultrasound (US) or computed tomography (CT) provide excellent visualization 
and control during placement of the RFA probe. However, these modalities do not offer in situ monitoring of 
the heat distribution. Therefore, treatment planning only involves manufacturer-specified heating protocols, 
which neglect patient-specific parameters. However, the heat sink effect of proximal vessels26 or the amount 
of porous tissue perfusion, affect the heat transfer and thereby shape and size of the lesion. Consequently, a 
simulation model adapted to the physiology can generate more accurate predictions. Therefore, it is desirable 
to use patient-specific data for treatment planning and modeling. Contrast-enhanced CT (ceCT) imaging allow 
determination of the vascular anatomy and quantification of the liver perfusion. Moreover, for accurate simu-
lation of the thermally induced lesion around the RFA probe, its precise location in situ is essential. Breathing 
motion of the liver makes reproduction of pre-interventional planning almost impossible. This raises the need for 
co-registration of planned needle positions and images acquired during the intervention.
For the past two decades, researchers have utilized advanced technologies to visualize the internal anatomy 
of the body in 3D. Since the probe positioning plays a critical role in the RFA procedure18,22,27–29, a comprehen-
sive visualization system containing both 2D and 3D views is important. Several RFA treatment planning and 
simulation environments have already been developed, for instance, a simulator and planner software solution 
for cryotherapy and its extension to RFA30. Further applications for RFA treatment planning exist utilizing dif-
ferent parameters spaces exist; e.g. RF-Sim tool22, MAXIO31, Robio17 and SAFIR27,32. GoSmart33 also features 
RFA simulations, but focuses more on providing a testbed for developers of hardware and software components 
and offering a communication platform between clinical and technical researchers, while high performance and 
integration into the clinical routine are not part of its scope. A first basic version of the RFA Guardian software 
has already been developed by the consortium in the EU FP7 project IMPPACT34. However, this predecessor did 
not support GPU acceleration.
The above software environments either require large supercomputers, which are not practical in the clinical 
environment, or lose accuracy as they omit patient-specific parameters. The proposed RFA Guardian rectifies 
these deficiencies as it has been developed to predict the treatment outcome in a couple of minutes while respect-
ing all relevant patient- and device-specific parameters.
The RFA Guardian. A comprehensive, user-friendly planning and simulation application for RFA needs 
to address the following scenarios within a single, local environment: (1) pre-interventional (PrI) simulation, 
which includes parameter space sampling for uncertainty estimation, prospective prediction of tumor coverage 
and correlated optimization of treatment cycles and access paths, (2) peri-interventional (PeI) simulation for the 
confirmation of parameterization in advance of treatment, reacting to unforeseen circumstances and concurrent 
simulation and treatment for confirming success, and (3) post-interventional (PoI) simulation aiding in training 
and education, examination of outcomes in advance of patient monitoring, and investigating failed treatment.
For easy integration into the clinical workflow, it is necessary that such a comprehensive application performs 
all computations in a fast and accurate manner. Moreover, the application needs to efficiently exploit the available 
standard hardware on a single high-end PC, instead of an expensive, often external, distributed computing cluster. 
Finally, all mentioned scenarios and their respective algorithmic requirements should be included in a single, 
user-friendly interface.
The presented RFA Guardian employs a generalized medical workflow, capturing the commonalities observed 
in four European clinical sites. It provides means for patient-specific modeling, faster-than-real-time simulation 
on the graphics processor (GPU) and advanced visualization for validating real and simulated treatment. We 
focus on exploiting all capabilities of a single PC for optimized performance, both in terms of time and accuracy. 
While automatic access path optimization is not part of the implemented feature set, the overall flexibility and 
high performance of the RFA Guardian allow for a straight-forward extension in this direction in future work.
IRs of any experience level can benefit from using the RFA Guardian for planning, validation and investiga-
tion. Moreover, its modularity also provides a testbed for device vendors and researchers.
Methods
The RFA Guardian is an integrated, single PC application, combining a considerable number of image processing, 
biomechanical simulation and visualization algorithms into a single ergonomic interface. The focus on high com-
putational performance enables fast and accurate simulation of the RFA treatment in PrI, PeI and PoI scenarios. 
The basic GUI (Fig. 1) resembles standard radiological workstations and includes an extensive set of features for 
different use cases with simple means for manipulation. Multiple, adjustable views for inspecting patient data 
occupy the largest part of the interface (Fig. 1, center). Additional key elements offer management and adjustment 
of input and generated datasets (Fig. 1, left) and control elements for executing tasks in the technical workflow 
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(Fig. 1, right). Before detailing the feature set of the RFA Guardian, the upcoming section introduces the intended 
use cases resulting both from clinical and technical demands.
Use Cases. From the clinical perspective, several scenarios for simulation of RFA treatment of liver tumors 
arise. Prospective prediction of the effects of certain parameterizations or exploring the parameter space and the 
resulting ablation zones can be critical tools in planning treatment. For education or evaluation purposes, retro-
spective simulation of real treatment configurations is important. The RFA Guardian aims at covering as many 
scenarios as possible with its comprehensive feature set. Table 1 shows a brief overview of the use cases and which 
features they use, while the upcoming subsections provide a bit more detail on the different intentions.
Pre-Interventional Planning (Pr-1). This scenario aims at finding appropriate access paths and positioning for 
the needle before the intervention. Prospective simulation allows the IR to estimate the outcome in a safe scenario 
and to translate the insight into a real treatment procedure for that patient. This also includes the parameterization 
Figure 1. The RFA Guardian interface, showing a case from the pre-clinical evaluation. The left-most part is 
the data manager, a collection of all data loaded and generated during the workflow. The large central area is 
reserved for visualization, containing three orthogonal slice viewers and a 3D representation. The right part 
contains the control elements for navigating through the technical wokflow.
Step
Pre-Interventional Peri-Interventional Post-Interventional
Pr-1 Pr-2 Pe-1 Pe-2 Pe-3 Po-1 Po-2
Model x x x x x x x
Virtual Needle Placement x x x (x) (x) (x) (x)
Real Needle Segmentation (x) (x) (x) (x)
Needle Registration o (o) (o) (o) (o)
Simulation x x x x x x
Simulation Parameter Sampling o x (o) (o) o
Real Lesion Segmentation x x x
Real Lesion Registration x x x
Statistical Evaluation o o x x x x o
Visualization-Guided Evaluation o o o o o o o
Table 1. Features of the RFA Guardian contributing to the various usage scenarios. x and o denote mandatory 
and optional modules, respectively. Items in brackets highlight branching workflows, mostly resulting from 
the underlying data. Especially the needle definition depends on whether the real needle is visible and requires 
registration into the PrI model. Using parameter space sampling, on the other hand, depends on whether tissue 
parameters can be precisely estimated or measured for a given case.
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of the device, e.g. selecting appropriate heating protocols. From the perspective of the day-to-day clinical routine, 
this is probably the most important scenario, since it reinforces the current planning routine that rarely relies on 
accurate prediction software.
Pre-Interventional Parameter Space Sampling (Pr-2). This is an extension of the planning procedure Pr-1 for 
cases where estimating tissue parameters or accurate reconstruction of planned needle positions are difficult. In 
such situations, generating an ensemble of simulations with slightly varying parameterizations can help the IR to 
estimate the variance of possible treatment results. For example, if no navigation systems aid the IR in faithfully 
reproducing needle positions are available, simulating with multiple, slightly varying needle positions can provide 
a good estimation the possible range of results.
Peri-Interventional Prospective Planning (Pe-1). Besides PrI simulation, the RFA Guardian is the first of its kind 
that could enable simulation during actual treatment in the clinical routine due to its high performance simula-
tion. While the patient is under general anesthesia, the IR can place a virtual needle in PeI images, register it into 
the PrI model and predict the outcome. This parameterization could, for example, serve as input into a navigation 
system which faithfully reproduces the positioning.
Moreover, a limited number of iterations for parameter space sampling is feasible within a reasonable 
timespan.
Peri-Interventional Prospective Confirmation (Pe-2). Similarly to Pe-1, the IR can segment and register an 
already placed, real needle prior to treatment and use this parameterization for simulation. In case the resulting 
predicted coagulation area is unsatisfying, the IR can still adapt the treatment plan. This scenario, where treat-
ment and simulation run in parallel, is currently being investigated in a clinical trial35.
Peri-Interventional Retrospective Validation (Pe-3). The final shape and size of the coagulated region is ambig-
uous up until about one month after treatment. Simulating the treatment concurrently with the actual ablation, 
allows the IR to visualize the final result in-situ and perform minor corrections, such as additional heating cycles, 
during treatment.
Post-Interventional Retrospective Validation (Po-1). This use case is similar to Pe-3, but lacks the option to react 
to possible shortcomings in-situ. Still, if the IR detects issues retrospectively, they can decide to adapt monitoring 
intervals or arrange additional treatment. Further, we believe that this can be exploited in educating inexperi-
enced IRs.
Post-Interventional Evaluation (Po-2). In the worst case of an unsuccessful treatment, retrospective evaluation of 
error sources can provide additional insight, both for education and future cases. For instance, the user can trace 
the effects of the power deposition and reason on the cause for failure.
Technical Workflow. In the clinical routine, the workflow for CT-guided RFA treatment follows a rather 
straightforward path. First, the IR in charge plans the treatment according to available patient data, e.g., using 
diagnostic imaging. The intervention plan includes the number of required heating cycles with their respec-
tive parameterization and needle positioning. During the intervention, the IR implements the planned proce-
dures step by step and at the end of the intervention checks size and shape of the coagulated region on ceCT 
images. After treatment, patients undergo follow-up imaging at regular intervals to detect potential (local) tumor 
recurrence.
The RFA Guardian further generalizes the workflow to aid the IR during the following three phases: (1) The 
Modeling Phase, for generating a patient-specific model comprising of anatomic structures and tissue-related 
parameters out of ceCT data; (2) The Simulation Phase, for accurate and quick estimation of the outcome of 
one or multiple treatment cycles, incorporating patient- and device-specific parameters and (distinct) needle 
positions. In addition, the RFA Guardian also provides parameter space sampling methods for mitigating uncer-
tainties, e.g. arising during data collection or needle placement; (3) The Validation Phase involving quantitative 
assessment of treatment success, as well as advanced visualization for more in-depth analysis. Figure 2 provides 
an overview of the relationship between technical tasks and the medical workflow.
Modeling Phase. The Modeling Phase serves as an initial stage for fusing patient information into a single 
model for simulation. Since patient-specific anatomy plays a significant role in the precise prediction of RFA12,13,36, 
we incorporate fast and accurate image processing methods for segmentation and registration and allow for man-
ual correction. Patient- and device-specific parameters, which the RFA Guardian accepts through its interface, 
complete the patient-specific model.
The first step is automatic segmentation of the liver37 from a PrI ceCT image. The segmented liver capsule 
delimits the region for computation, preventing unnecessary computations in remote locations, and thereby 
increases the performance. It also serves as an important parameter for registration throughout of the RFA 
Guardian.
Since vascular structures in proximity to a RFA probe strongly influence the heat diffusion, the RFA Guardian 
consecutively registers multiple ceCT PrI images into a common coordinate system using fully automatic pro-
cedures. Although optional, optimal accuracy can only be achieved by using a ceCT image each for the arterial, 
portal venous and hepatic phases during processing. For the remainder of the paper, we assume availability of all 
ceCT phases.
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Usually, all ceCT scans are recorded with minimal patient movement. However, motion correction38 showed 
to be mandatory and was therefore implemented to compensate anatomical discrepancies between individual 
phases due to breathing. From these registered images, the vessel trees are then automatically segmented39.
Due to the considerable computational demand, these steps are comparably time-consuming. To avoid con-
stant attendance of the user, most of the procedures have been automatized in a feed-forward pipeline. After 
assigning loaded ceCT images to their corresponding phase, a single mouse click is sufficient for computing this 
pipeline. The set of segmentations (liver outline and vessel trees) resulting from this pipeline forms a registered 
patient-specific anatomical model. For difficult cases, the RFA Guardian additionally offers tools for manual cor-
rection of non-optimal results in each step.
The tumor segmentation completes the patient-specific anatomical model. Unfortunately, automating this step 
is barely feasible. Different tumor types expose varying tissue parameters and arbitrary localization, so we resort 
to a semi-automatic region growing approach40 using user-defined seed points. For tumors with heterogeneous 
tissue density, multiple seed points may be required. The user can choose to combine or neglect the single seg-
mentation parts resulting from multiple seed points. Again, for very difficult cases, the RFA Guardian provides 
manual refinement tools. Moreover, to avoid an additional registration step, the seed points are defined directly 
in the registered ceCt images from the previous automatic pipeline.
The simulation domain is then defined by creating an optimized volumetric mesh for finite element (FE) 
simulation41, centered at the tumor. All previously created registered segmentations are fused into a single, space 
filling, tetrahedral mesh. During RFA treatment, the effect of heat deposition diminishes with distance from the 
probe, which is typically inserted close to the tumor. These observations enable optimizations of the simulation 
domain: Firstly, it is restricted in size. Since standard RFA protocols in the liver exhibit maximum coagulation 
diameters of 5 cm, the overall simulation domain is limited to a sphere with 6 cm radius around the tumor. Tissue 
beyond this border typically does not exhibit considerable influence on the heat distribution due to the large 
distance. Secondly, adaptive resolution techniques focus higher accuracy into critical regions. Especially the inter-
action around the tumor surface and near large vessels is important and requires a high FE mesh resolution. In 
mostly homogeneous tissue, the resolution can be lower and, consecutively, decreases the computational demand 
for these portions.
Simulation Phase. The FE mesh resulting from the modeling phase forms the domain for the simulation. 
The workflow of this stage splits up into several branches, depending on the use case. In a nutshell, the basic steps 
comprise definition of device-specific and patient-specific parameters as detailed below.
Needle Definition. The user can choose between placing a virtual needle model, or segmenting and registering 
a real needle from PeI CT imaging. The choice depends on the specific scenario and available data, but both ulti-
mately yield comparable input parameters.
Real Needle: From a PeI CT image, the user can segment and register a real needle. Both prospective and 
retrospective scenarios profit from accurately reconstructing the geometry, e.g. of umbrella-shaped probes. These 
Figure 2. The technical workflow of simulation in the RFA Guardian. When considering the clinical procedure, 
three distinct phases assert themselves: In the pre-interventional stage, diagnostic scans contribute to generating 
a patient-specific anatomical model and potentially allow inference of parameters relevant for the simulation. 
This model allows for high-performance simulation in the peri-interventional phase with user-defined 
parameterization of the needle and generator. Finally, the post-interventional phase serves for validation 
purposes and potential analysis tasks for optimizing the treatment in advance.
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often feature mechanically changeable extensions for different ablation sizes. We devised a simple, yet accurate 
and effective workflow for determining these needle geometries: In a patient image, the user manually selects 
the needle tip and a point along the shaft for simple models, and additionally the single prongs of extensible 
umbrella-shaped needles. For varying extensions that are not recorded in images, a simple interpolation (or 
extrapolation) from the input geometry is sufficient to accurately reconstruct the geometry.
The consecutive registration of this geometry into the PrI model employs the following strategy. First, the user 
needs to resolve large spatial deviations (e.g. occurring due to lateral positioning of the patient, or different offsets 
of different scanners) via picking a set of matching landmarks in the PeI images, as well as the PrI needle image. 
To simplify this process, the RFA Guardian provides axial and sagittal views of both images side-by-side. This 
allows to accurately localize and select landmarks in both images concurrently.
Using these landmarks, the RFA Guardian enforces a fast rigid registration method. In many cases, this opti-
mally matches the images from PrI and PeI scanning sessions. However, RFA needles exhibit a certain flexibility, 
possibly leading to deformation and deviation from the optimal shape. Moreover, previous partial liver resection 
can complicate the process. Therefore, rigid registration can lead to insufficient accuracy, raising the need for an 
additional deformable registration method38 to compensate for local deformation. The previously defined land-
marks already provide a good initialization for this method and, in most cases, further improve the registration 
accuracy.
Virtual Needle: Virtual needle placement is relevant for prospective planning, but can also act as a fallback for 
other scenarios, e.g. if the needle geometry is unavailable or obstructed in PeI images.
The user can place a virtual needle either directly in the PrI simulation domain, or relative to a PeI image. 
Generally, the virtual needle geometry can be defined using the intersection point between the needle tip and the 
tumor and a trocar point, which is any point along the needle shaft. However, more intricate needle models, for 
instance from Boston Scientific and RITA, exhibit a more complex geometry. This additionally requires param-
eterizing the rotation around the axis defined by the trocar and intersection. While manually replicating the 
exact positioning of the virtual needle for a real patient can be difficult, many clinics nowadays routinely employ 
navigation systems. If the user places a virtual needle to fit the real model in a PeI image, the same registration 
procedures as for real needle identification apply.
Device-Specific Parametrization. Apart from the needle positioning, device-specific heating profiles play an 
important role in the simulation process. The heating profiles are vendor-defined procedures, comprising dura-
tion of heating, cooldown cycles, iteratively extending umbrella-shaped needles, target temperatures, wattage, 
and many more. Again, the most complex procedures result from the umbrella-shaped probes, e.g. from RITA 
devices. The RFA Guardian implements predefined sequences, as provided by the vendors, and let the user choose 
the appropriate protocol. Although standard presets for target temperatures and power emission are provided by 
the RFA Guardian, the user can also modify these to correlate to the settings used during real treatment.
Patient-Specific Parameterization. Besides device-specific parameterization, measuring or estimating 
tissue-specific values contributes to the overall prediction accuracy. Perfusion measurements for healthy and 
malignant tissue are nowadays often part of the clinical routine. Other parameters, such as specific heat capacity 
or thermal conductivity, can often only be estimated. Nevertheless, the RFA Guardian provides interface elements 
for injecting these values into the simulation in case they have been measured or can be estimated accurately.
Parameter Space Sampling. Often, uncertainties exist when simulating RFA treatment. These can result from 
difficulties in reproducing planned needle positions or when measuring patient-specific parameters. However, the 
high performance of the implemented simulation strategy enables generation of multiple predicted coagulation 
zones in reasonable time spans. If the user is uncertain of certain inputs, they can choose up to two parameters 
(p1, p2) to simultaneously vary with (#itp1, #itp2) iterations, respectively. This results in itp1 * itp2 distinct configu-
rations which are then simulated distinctly. The variable parameters include tissue perfusion, tumor perfusion, 
specific heat capacity and thermal conductivity, For these, the user specifies the variation range, number of itera-
tions, and whether to randomly sample within this range, or linear interpolate is used.
The final variable parameter is the needle geometry. For simple models, typically only the tip and shaft orien-
tation are of interest. For complex shapes, however, the single prongs are of particular interest. The flexibility of 
these instruments can lead to varying distances between the prongs, and, consecutively, modify the energy distri-
bution. Here, the user can choose how many of the prongs should be considered for variation and the deviation 
range r (in mm). These points, including the needle tip, point on the shaft and potentially the single prongs, have 
their initial values set to the result from the Needle Identification and registration procedures. Variation is then 
achieved by moving the single positions in random directions within a sphere of size r, centered at the original 
point. Again, the user can choose how many iterations and, consecutively, different needle geometries, should be 
considered for the simulation.
The resulting itp1 * itp2 predictions are then visualized for closer inspection by the user. Standard visualization 
techniques (Fig. 3) fail to provide the necessary insight into the resulting simulation ensemble. Especially the 
density of results is hard to determine in certain areas, leading to difficulties in predicting the outcome. Hence, 
the RFA Guardian implements a variation of Contour Boxplots42 to provide the user with an overview of what 
variations to expect. Figure 4 presents a simplified version of the same ensemble, highlighting the median, var-
iance, outliers, and critical vessels. In combination with toggling certain parameter ranges on/off, the user can 
analyze the range of results to expect within the provided parameter variation and, potentially, optimize treatment 
parameters in advance.
www.nature.com/scientificreports/
7Scientific REPORTS |  (2018) 8:787  | DOI:10.1038/s41598-017-18899-2
Simulating Single and Multiple Cycles. After defining the simulation parameters, the user initiates the 
GPU-based computation. For any simulation scenario, the power deposition is computed using Gaussian distri-
bution25 around the needle tip. This produces temperature distributions according to Penne’s bioheat equation43. 
A temperature-dependent three state cell death model44 is used to predict the cell death likelihood. The predicted 
coagulation volume is then extracted as described in literature41. A massively parallel GPU implementation41 
provides the desired computational performance. For instance, 5 cm ablation protocols take roughly 3 minutes to 
compute, while the corresponding real ablation protocol takes at least 15 minutes.
The visualization section of the RFA Guardian continuously displays the outline of the coagulated area during 
this process. This real-time lesion tracking can provide valuable insight for the operator, e.g. when observing the 
behavior in critical regions.
After computation finishes, the simulation module goes into an idle state, waiting for additional input for 
further ablation tasks. After executing the first standard protocol, the user can perform additional heating in 
the same needle position with customizable duration, or conduct additional protocols using different needle 
positions. This is often the case in clinical routine, where tumor size or shape may demand multiple protocols. 
Although, usually, the number of cycles is reasonably low, unlimited, arbitrary combinations of standard and 
additional heating procedures are possible. For convenience, parameterization of each cycle is stored. This enables 
the user to replay each step of the simulated treatment and explore different strategies.
Figure 3. A simulation ensemble generated from the parameter space sampling routine. This particular set 
contains 25 simulation results while varying perfusion of tumor and tissue concurrently, with 5 linear variations 
each. Even small uncertainties in measuring the parameters can already have a considerable impact on the 
outcome. However, the parameter space sampling allows the user to estimate the expected range of results.
Figure 4. The same ensemble as in Fig. 3, but visualized with Contour Boxplots42. The simplification and 
consecutive condensation of information into a median (dark blue) and respective variance (medium blue and 
light blue), in conjunction with outliers (orange) and vessels (red), provides more insight into the behaviour of 
the lesion under varying parameters. Using this technique, the user can reason whether, e.g. the vessel is likely 
to be coagulated or survive. Factors like this can be critical in treatment planning, but are often overlooked in 
planning applications.
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Validation Phase. In general, planning RFA prospectively requires accurate and reliable predictions. In the 
Validation Phase, several techniques catering to the different usage scenarios aid the user in evaluating real or 
simulated results with a number of computed metrics. From a technical perspective, this can help in assessing the 
quality, while, from a clinical perspective, this can improve the trust in prospective planning based on simulation. 
The tasks basically boil down to comparing meshes and evaluating the distance and overlap between them. In case 
of comparing real and simulated coagulation zones, the distance should be minimized and the overlap should be 
high. When comparing simulated or real treatment to a tumor, investigating the safety margin around the tumor 
is critical, which implicitly also covers overlap measurement.
The RFA Guardian provides several metrics from literature25,41,45 for comparing two meshes. The indicators 
can be subdivided into two groups. For one, the distance between the meshes, condensed into the average abso-
lute error (AAE) and minimum/maximum 3D distance are important. Additionally, volumetric measurements, 
including the relative volume difference (RVD) and sensitivity are provided.
In many cases, validation additionally requires registration and segmentation of real treatment results. The 
real lesion shape and size only manifests in the ceCT control one month after RFA treatment, which the user 
needs to segment from PoI images and consecutively register into the PrI model.
Real Treatment vs. Tumor. While this use case plays a lesser role in the RFA Guardian, it is still possible to eval-
uate real treatment within the application. Comparing a tumor, segmented from PrI images, with a segmented 
and registered real lesion, yields information about treatment success, e.g. whether the required safety margin is 
respected.
Simulation vs. Tumor. For prospective planning, the RFA Guardian enables comparison between a simulation 
outcome and the tumor. Similar to real treatment, the most important metrics to inspect are AAE and minimum/
maximum distance between the predicted coagulation zone and the segmented tumor. In this scenario, registra-
tion and segmentation are obviously not necessary and the user can simply select the simulation result as input 
for the metrics computation.
Simulation vs. Real Treatment. During development, this was the most important use case. For comparing a 
simulated lesion with real treatment, segmenting the coagulation zone from a PoI image and registering it into 
the PrI simulation domain is often necessary. However, the significant time span between PrI images and PoI 
follow-up leads to considerably higher abdominal deformation compared to the short interval between PrI and 
PeI phase. Further, the region around the coagulated area tends to shrink over time, an effect that appears to be 
strongest in non-cirrhotic livers. These factors lead to the definitive need for deformable registration procedures 
to match the patient anatomy, similar to the PeI needle image registration.
The user then compares the registered, segmented real lesion with the simulation result. In this case, a few 
more metrics are relevant. Besides AAE and minimum/maximum distance between the meshes, additional vol-
umetric considerations are important. During preliminary evaluation of the RFA Guardian, an intervention was 
considered to be successful41, if the RVD <20%, sensitivity >80% and AAE is below 3 mm.
In-Depth Simulation Investigation. In case the IR is not satisfied with the simulation result, determining the spe-
cific problematic areas in state-of-the-art software typically requires tedious, time-consuming manual measure-
ments and slice-by-slice evaluation. To remedy these issues, the RFA Guardian provides advanced visualization 
techniques46. The implemented approach provides three consecutive stages of evaluation. While the algorithm 
is capable of catering to a wider range of scenarios, the RFA Guardian mainly exploits direct comparison of a 
simulation result to a given segmented tumor. The first stage enables fast evaluation whether the necessary safety 
margin (typically, 5 mm) between coagulated region and tumor is satisfied by a simulation result. The visuali-
zation displays a thick, color-coded rim at the outline of the coagulated region in 2D. The color coding catego-
rizes portions of the outline into definitely failed (distance < 4.5 mm), critical (4.5 mm < distance < 5.5 mm) and 
probably safe (distance > 5.5mm). While scrolling through the slice stack, the user gets a quick overview of the 
successfulness of a parameterization. Moreover, the algorithm provides multivariate visualization techniques for 
in-depth analysis of the simulation domain. The user can choose two parameters that are additionally visualized. 
The first variable is encoded using adjustable, colored iso-bands. These are similar to iso-contours, but addition-
ally encode gradients in the underlying field via a custom width with a smooth fall-off at the margins. The second 
variable is customly categorized and displayed using structural elements.
While the first technique provides a fast qualitative overview for the operator of the RFA Guardian and is 
applicable in the day-to-day clinical routine, the multivariate analysis caters more towards experts in the biome-
chanical simulation field.
Implementation
All previously mentioned algorithms were implemented in C++, exploiting the open source MITK47 framework, 
which provides basic functionalities for medical workstations. The single modules rely on VTK (http://www.vtk.
org) for visualization tasks, while all image processing algorithms have been implemented in the ITK (http://
www.itk.org) framework. The FE mesh creation was implemented in the Computational Geometric Algorithms 
Library (CGAL http://www.cgal.org) and Gmsh (https://www.gmsh.info). The simulation procedures exploit 
massively parallel GPU acceleration via NVidia CUDA (http://www.nvidia.com/object/cuda).
The interface frontend implements predictive schemes to hide the complexity of the workflow during interac-
tion and simplifies the usage of the RFA Guardian. Connected tasks were grouped into coherent interface blocks. 
Depending on both user interaction and available data, only the methods specifically relevant to the possible 
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scenarios are enabled. The GUI comprises components of MITK, but futher extends the Qt (http://www.qt.io) 
library for specific tasks.
Results
The RFA Guardian has been evaluated in a pre-clinical trial, especially in terms of its capabilities for PoI simu-
lation and PrI planning. Data of previously treated cases, exposing heterogeneous imaging protocols, served as 
benchmark for testing. Further, the technical workflow has been optimized towards the final objective, namely 
PeI prospective simulation of treatment with the RFA needle in place. Since the clinical trial employing the RFA 
Guardian is still ongoing, final data for this objective is not yet available. Instead, results based on the PoI simu-
lation of real cases are presented. These are analyzed in terms of time requirements per workflow step. Especially 
the simulation phase, including needle identification, needle registration and simulation itself, is time-critical 
for PeI simulation. Secondly, the predicted coagulated areas need to be accurate with respect to the results of real 
treatment. We received consensus for disclosing the data from five patients and provide them online along with a 
viewer application for reference at http://www.numa.ie/rfaguardian.
Workflow Duration. During the evaluation phase, several IRs from four European clinics recorded the time 
required for each step of the whole RFA Guardian workflow while executing 10 cases from clinical practice retro-
spectively. Table 2 summarizes the records. In the following breakdown, the timings are annotated as (Average/
Standard Deviation) in minutes.
As expected, the automated part of PrI modelling is comparably time consuming (21.4/5.4). Tumor segmen-
tation including manual correction (5.0/1.8) and volumetric meshing (5.5/1.2), however, are comparably fast and 
add little to the overall modelling duration (28.5/7.0). For simulating the first ablation cycle, the IR performed 
segmentation of umbrella-shaped needles (5.5/1.5) and landmark selection (5.8/1.8) for registering (2.8/1.36) 
the PeI images into the model before simulating (2.5/1.3). Moreover, four cases include a second ablation cycle, 
again requiring needle segmentation (5.5/1.0), landmark picking (2.8/0.9), registration (2.0/1.0) and simulation 
(1.5/0.5). In our opinion, the whole simulation procedure (16.6/2.8 first cycle; 11.75/2.25 second cycle) of the RFA 
Guardian is fast enough to justify the PeI prospective simulation goal and, in the future, effectively assist IR in 
the clinical routine. For completeness, the IR performed ablation zone segmentation (3.9/1.7), landmark picking 
(4.8/1.0) and registration (1.5/0.6) for images one month post ablation.
Simulation Accuracy. As previously described, the success of simulation with the RFA Guardian is deter-
mined by evaluating how well the shape and size of the predicted lesion match those of the real treatment. On 
top of the temporal assessment, a multi center retrospective study has been conducted on 21 previously treated 
cases41. Statistical evaluation of these cases (Table 3) shows that the simulated lesion based on the RFA Guardian 
and the treatment outcome match quite well. Figure 5 shows a few comparisons between simulated and real coag-
ulation areas, also exposing a good visual match.
For five of these cases, the results were below our expectations. Special difficulties have been observed during 
evaluation of tumors in non-cirrhotic livers. There appears to be a certain amount of post-ablation shrinkage in 
Step
Pre-Interventional
Automatic liver model Tumor Segmentation Volumetric Meshing
Average (minutes) 21,40 5,00 5,50
Standard Deviation 5,40 1,80 1,20
Sum (Std. Dev.) 28,5 (7,0)
Step
Peri-Interventional, 1st cycle
Needle Segmentation Needle Registration Simulation
Average (minutes) 5,50 8,60 2,50
Standard Deviation 1,50 3,16 1,30
Sum (Std. Dev.) 16,6 (2,8)
Step
Peri-Interventional, 2nd cycle
Needle Segmentation Needle Registration Simulation
Average (minutes) 5,50 4,80 1,50
Standard Deviation 1,00 1,90 0,50
Sum (Std. Dev.) 11,75 (2,25)
Step
Post-Interventional
Lesion Segmentation Lesion Registration
Average (minutes) 3,90 6,30
Standard Deviation 1,70 1,60
Sum (Std. Dev.) 10,2 (3,3)
Table 2. Timing for the different phases while using the RFA Guardian to simulate treatment in the post-
interventional validation scenario (Po-1). While the pre-interventional steps are comparably time consuming, 
the peri-interventional simulation using placed needles (and the corresponding segmentation and registration 
tasks) are comparably fast. The statistics contain ten similarly structured cases from the clinical routine.
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the comparably soft liver tissue for these patients. This induces considerable errors in the deformable registration 
procedure. For reference, we cross-validated these cases using a straight-forward rigid registration that only con-
siders the lesion outlines and disregards the surrounding tissue. In some of these cases, we could indeed confirm 
the liver shrinkage as the source of the error. For the remaining cases, however, we could only trace back the 
remaining inaccuracies to the needle registration procedure. Even minor errors, such as moving a single needle 
tip closer (or into) a major vessel has a strong influence on the faithfulness of the prediction.
Another key factor that limits the achievable simulation accuracy is track ablation, performed to reduce the 
risk ot tumor seeding in the access path. While frequently used in clinical routine, simulating this procedure 
is infeasible since it involves slow, manual retraction of the probe without a fixed protocol. However, it is at 
the same time impossible to discriminate between portions induced by track ablation and normal treatment. 
Consecutively, the track ablation must also be considered in the accuracy evaluation and further diminishes our 
results.
Figure 6 shows an especially difficult case. The tumor is comparably small (7 mm), which amplifies even small 
registration inaccuracies, and is located at the liver capsule. The mechanical force applied by inserting the needle 
leads to considerable tissue deformation, a factor we observed to be much larger for peripheral tumors compared 
to centrally located ones. Further, the liver is non-cirrhotic, implying larger deformations due ot the mechanical 
Metrics DSC(%) RVD (%) SN (%) PPV (%) AAE (mm)
Mean 70,03 13,77 69,70 71,73 2,44
Standard deviation 9,37 12,96 10,94 12,00 0,84
Table 3. Comparing simulation results obtained in the RFA Guardian versus real treatment for 21 cases. 
Despite imaging procedures and parameter acquisition not being optimized and heterogeneous, we still achieve 
high accuracy. The table lists Dice Score (DSC), Relative Volume Difference (RVD), Sensitivity (SN), Positive 
Predictive Value (PPV) and Absolute Average Error (AAE).
Figure 5. Visual comparison of six distinct simulation results (color-coded opaque mesh) and the respective 
segmented real lesions (green transparent surface). Despite non-optimal imaging conditions and protocols, the 
accuracy achieved during pre-clinical evaluation of the RFA Guardian is very promising.
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force. Additionally, the track ablation is comparably large with respect to the locally induced ablation. The com-
bination of these factors lead to an unsatisfying result (DSC 69.07, RVD 81.28, AAE 4.57).
Discussion
This paper presented the RFA Guardian, a comprehensive application for covering a broad range of use cases 
for simulating the RFA of liver tumors in the clinical routine. Using a uniform workflow, capable of branching 
towards handling exceptions or deviations from standard processes, the RFA Guardian provides a flexible frame-
work that can be used for PrI planning, PeI prediction and evaluation and PoI analysis in the clinical routine.
Currently, the RFA Guardian is the center of a clinical trial35 that evaluates whether peri-interventional 
prospective simulation could be feasible in the future. To ultimately achieve this goal, the focus of the ongo-
ing study is to record the time required for simulating treatment using a real needle position, segmented from 
peri-interventional images and registered into the patient-specific model. Of course, simulation accuracy is 
another critical end-point of the trial.
An early observation of this study is the need for two persons involved in the workflow: One person (an IR 
or technical assistant) is responsible for operating the software, while the IR can fully focus on the treatment. 
While moving from the pre-clinical trial to the clinical study, a considerable training effect has been observed 
for the peri-interventional tasks: While needle segmentation and registration, as well as simulation initially took 
up to 30 minutes per treatment cycle, the current average is at 16.6 minutes for the first and 11.75 for the second 
cycle (see Table 2). Discussions with the IR involved in the study suggest that the gain from accurate prospective 
simulations could outmatch the additional time requirement. Further, we believe that specialized training and 
increasing experience of the operator can further decrease the required time. Of course, future image processing 
and simulation techniques could also contribute to reducing the time requirements. Nevertheless, the IR revealed 
that integrating the RFA Guardian in its current state could provide sufficient benefit justifying the additional 
time requirements.
Since general anesthesia is part of the standard protocol of all clinical sites involved in the study, only using 
local anesthesia has not been considered. Feasibility of PeI prospective simulation under these circumstances 
definitely requires a separate trial.
The preliminary results (Section VII) show that the RFA Guardian is capable of fast and accurate prediction 
of intervention outcomes. This was only possible due to careful optimization of algorithmic and user aspects. 
Nevertheless, in some cases, the results are still below our expectations. In terms of accuracy, registration between 
the three imaging phases can be difficult. From a technical point of view, it would be highly desirable to move the 
complete modeling phase into the peri-interventional phase, which would lead to improved accuracy of image 
registration between the patient model and the needle images. However, this could mean excessive time under 
general anesthesia for the patient. Hence, the only way to improve this aspect is to explore other possibilities for 
registration between pre-interventional and peri-interventional images. When considering navigation systems, 
Figure 6. Visual comparison of an unsuccessful case with a tumor at the liver capsule. This particular 
case was treated with two consecutive ablation cycles with needle repositioning inbetween (left and center 
images). While the registration between real induced lesion (green) and tumor (yellow) seems appropriate, 
the registration of the needle geometry was not accurate enough due to severe tissue deformation at the liver 
capsule. The left and central figures shows an idealized needle model in gray, while the red spheres visualize the 
actual simulation input. These single tips resulted from segmentation and registration of the patient images for 
this case. The deviation from the optimal umbrella shape consecutively leads to a mismatch between simulated 
and real treatment (right), is below the necessary accuracy. However, such registration mismatches are typically 
easy to identify during the workflow and, consecutively, do not pose a risk for patients if observed carefully.
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this is especially crucial for reproducing planned needle positions. However, these issues only occur in special 
cases, for instance in non-cirrhotic livers.
From a validation point of view, the considerable deformation observed in the post-interventional moni-
toring images, especially near the coagulated region, induces additional inaccuracies. In our opinion, this issue 
requires completely new image registration techniques that base on accurate analysis of tissue flexibility after RFA 
treatment.
Although currently purposely focused on a narrow range of device vendors, extending the RFA Guardian 
to additional, often more simple RFA generators is straightforward. Focusing the development of the RFA 
Guardian around RITA probes from the start was a deliberate choice. Considering that these introduce consid-
erable complexity in terms of registration and computation, introducing simpler probes and generator models 
in future applications will be much easier than adapting the software the other way around. Further, extension to 
Microwave Ablation devices and their specific simulation setup is currently under investigation. This will provide 
capabilities for comparing different treatment modalities, allowing the IR to choose the best suited treatment for 
a patient.
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